Tinoco-Téllez LL, Marín-Santillán E, Gálvez-Valdovinos R, Alonso-Briones MV, Aguirre-Trigueros J, Funes-Rodríguez JF, Domínguez-Carrillo LG

Language: Spanish
References: 14
Page: 165-170
PDF size: 275.76 Kb.

ABSTRACT

Background: Pseudomyxoma peritonei is characterized by disseminated intraperitoneal mucinous tumors and mucinous ascites in the abdomen; with incidence of 1/1,000,000, it predominates in females; 30-50% of patients have progressive abdominal ascites, accompanied by abdominal pain, weight loss and dyspnea; in 90% of patients, the primary lesion is a mucinous tumor of appendix. Computed tomography and histopathology are the most reliable diagnostic modalities. Current treatment is debulking surgery combined with hyperthermic intraperitoneal chemotherapy, followed by intravenous chemotherapy. Clinical case: A 31 years old male with previous appendectomy eight years ago, with increasing of abdominal girth of two months, 8 kg weight loss and progressive dyspnea. On examination: globular abdomen by ascites, decreased peristalsis and no evidence of acute abdomen; he subjected to laparotomy with removal of six liters of ascitic fluid and debulking surgery accompanied by hyperthermic chemotherapy. 27 months after diagnosis the patient is rated in 1 of functional ECOG scale. Conclusions: Pseudomyxoma peritonei is a rare disease, its treatment includes debulking surgery combined with intraperitoneal hyperthermic chemotherapy.

REFERENCES

1. Sugarbaker PH. Pseudomyxoma peritonei.Cancer Treat Res. 1996; 81: 105-119.

2. Amini A, Masoumi-Moghaddam S, Ehteda A, Morris DL. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects. Orphanet J Rare Dis. 2014; 9: 71.

3. Sulkin TV, O’Neill H, Amin AI, Moran B. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol. 2002; 57 (7): 608-613.

4. Yan H, Pestieau SR, Shmookler BM, Sugarbaker PH. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation. Mod Pathol. 2001; 14 (3): 164-171.

5. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221 (1): 29-42.

6. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009; 249 (6): 900-907.

7. Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum. 1987; 30 (10): 772-779.

8. González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010; 2 (2): 68-75.

9. Huang Y, Alzahrani NA, Liauw W, Morris DL. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2015; 41 (10): 1373-1378.

10. Funder JA, Jepsen KV, Stribolt K, Iversen LH. Palliative surgery for pseudomyxoma peritonei. Scand J Surg. 2016; 105 (2): 84-89.

11. Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol. 2015; 41 (3): 396-399.

12. Carrillo ER, Nava LJ, Romero SG, Cáñez JC. Manejo perioperatorio de la quimioterapia intraperitoneal hipertérmica. Rev Mex Anest. 2014; 37: 193-200.

13. López BH, Morales VF, Luna OK, Méndez HC et al. Citorreducción e HIPEC en carcinomatosis peritoneal. Experiencia del Instituto Nacional de Cancerología de México. Cir Gen. 2014; 36: 138-144.

14. Tabrizian P, Shrager B, Jibara G, Yang MJ et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg. 2014; 18: 1024-1031.